may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists.
Testosterone: (Moderate) Use caution if coadministration of ribociclib with testosterone is necessary, as the systemic exposure of testosterone may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and testosterone is a CYP3A4 substrate.
Tetrabenazine: (Major) Avoid coadministration of ribociclib with tetrabenazine due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Tetrabenazine causes a small increase in the corrected QT interval (QTc). Concomitant use may increase the risk for QT prolongation.
Theophylline, Aminophylline: (Moderate) Use caution if coadministration of ribociclib with theophylline is necessary, as the systemic exposure of theophylline may be increased resulting in increase in treatment-related adverse reactions. Monitor for elevated theophylline concentrations and/or theophylline toxicity. Ribociclib is a moderate CYP3A4 inhibitor and theophylline is a CYP3A4 substrate with a narrow therapeutic window.
Thiopental: (Moderate) Coadminister ribociclib and thiopental with caution, as the systemic exposure of ribociclib may be decreased resulting in reduced efficacy. Ribociclib is extensively metabolized by CYP3A4 and thiopental is a CYP3A4 inducer.
Thioridazine: (Severe) Because of the potential for torsade de pointes (TdP), use of ribociclib with thioridazine is contraindicated. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Thioridazine is associated with a well-established risk of QT prolongation and TdP. Concomitant use may increase the risk for QT prolongation.
Tiagabine: (Moderate) Use caution if coadministration of ribociclib with tiagabine is necessary, as the systemic exposure of tiagabine may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and tiagabine is a CYP3A4 substrate.
Ticagrelor: (Moderate) Use caution if ribociclib is coadministered with ticagrelor, as the systemic exposure of ticagrelor may increase resulting in increased adverse reactions. Ribociclib is also a moderate CYP3A4 inhibitor, and ticagrelor is a CYP3A4 substrate. The exposure to ribociclib may also increase as ticagrelor is a weak inhibitor of CYP3A4 and ribociclib is extensively metabolized by CYP3A4. Monitor patients for adverse events.
Tinidazole: (Moderate) Use caution if coadministration of ribociclib with tinidazole is necessary, as the systemic exposure of tinidazole may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and tinidazole is a CYP3A4 substrate.
Tiotropium; Olodaterol: (Moderate) Due to a possible risk for QT prolongation, ribociclib and long-acting beta-agonists should be used together cautiously. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval like ribociclib. This risk may be more clinically significant with long-acting beta-agonists such as olodaterol as compared to short-acting beta-agonists.
Tipranavir: (Severe) Coadministration of ribociclib with tiprana |
